David Spencer - Bellicum Pharmaceuticals Insider

Bellicum Pharmaceuticals Inc -- USA Stock  

USD 6.60  0.63  10.55%

Co-Founder and Chief Scientific Officer

Dr. David M. Spencer, Ph.D. is Founder, Chief Scientific Officer of the Company. He founded Bellicum with Kevin M. Slawin, M.D. in July 2004 and served as a member of our Board until September 2004. He has served as a scientific advisor to the Company since our inception and has served as our Chief Scientific Officer since November 2011, a position that he also held parttime as a consultant since September 2004. From January 1996 to November 2011, Dr. Spencer served as professor in the department of Pathology and Immunology at Baylor College of Medicine and as Vice Chairman of the department from January 2010 to November 2011
Age: 53  Founder Since 2011  Ph.D    
832-384-1100  http://www.bellicum.com
Spencer is the original inventor of our CID technology, and together with Dr. Slawin, developed the first clinical applications of the technology, DeCIDe and CaspaCIDe. He received his B.A. degree in Chemistry from the University of California, San Diego and his Ph.D. in Biology at Massachusetts Institute of Technology and was a postdoctoral fellow at Stanford University.

David Spencer Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (37.63) % which means that it has lost $37.63 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (83.07) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 30.92 M in liabilities with Debt to Equity (D/E) ratio of 29.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Bellicum Pharmaceuticals Inc has Current Ratio of 5.96 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas. Bellicum Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ General Markets exchange. It employs 110 people.Bellicum Pharmaceuticals Inc (BLCM) is traded on NASDAQ General Markets in USA. It is located in TEXAS, U.S.A and employs 110 people. Bellicum Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Bellicum Pharmaceuticals Inc to your portfolio

Top Management

Bellicum Pharmaceuticals Leadership Team
Frank McGuyer, Director
Richard Fair, CEO, MBA
Stephen Davis, Director
Reid Huber, Director, Ph.D
Peter Hoang, President, MBA
Alan Musso, CFO
Kevin Slawin, Director
David Spencer, Founder, Ph.D
Jon Stonehouse, Director
James Brown, Chairman
Jim Daly, Director, MBA
Ken Moseley, President
Annemarie Moseley, President
James Daly, Director, MBA
Dennis Stone, Director
Thomas Farrell, CEO, MBA
William Grossman, Executive, Ph.D
Joseph Senesac, President, MBA

Stock Performance

Bellicum Pharmaceuticals Performance Indicators